金域医学(603882) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,117,566,265.14, a decrease of 50.19% compared to the same period last year[4] - Net profit attributable to shareholders was ¥149,613,208.46, down 82.40% year-on-year, while the net profit excluding non-recurring gains and losses decreased by 83.20%[4] - The diluted earnings per share were ¥0.32, reflecting an 82.42% decrease compared to the previous year[5] - Net profit for Q1 2023 was ¥140,616,978.25, a decline of 84.6% compared to ¥909,423,394.29 in Q1 2022[17] - Comprehensive income for Q1 2023 totaled ¥125,746,509.44, a decrease of 86.1% from ¥908,396,159.29 in Q1 2022[18] Cash Flow and Management - The net cash flow from operating activities was ¥219,822,454.05, an increase of 143.47% year-on-year, indicating improved cash management[4] - In Q1 2023, the net cash flow from operating activities was RMB 219,822,454.05, a significant increase from RMB 90,285,681.91 in Q1 2022, representing a growth of approximately 143.5%[20] - Total cash inflow from operating activities was RMB 2,471,627,822.23, while cash outflow was RMB 2,251,805,368.18, resulting in a net cash inflow of RMB 219,822,454.05[20] - Cash and cash equivalents at the end of Q1 2023 amounted to RMB 2,926,679,233.87, up from RMB 2,453,855,010.63 at the end of Q1 2022, indicating an increase of approximately 19.2%[20] - The company reported a decrease in cash paid for goods and services, which was RMB 1,027,974,829.24 in Q1 2023 compared to RMB 1,149,933,502.11 in Q1 2022, reflecting a reduction of about 10.6%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,409,369,919.34, a decrease of 3.47% from the end of the previous year[5] - As of March 31, 2023, the total current assets amounted to RMB 10,124,855,451.83, a decrease of 5.03% from RMB 10,659,634,227.24 on December 31, 2022[13] - Total non-current assets increased slightly to RMB 3,284,514,467.51 from RMB 3,231,073,610.50, an increase of 1.65%[14] - The company's total liabilities decreased to ¥4,388,202,903.12 in Q1 2023 from ¥5,015,880,313.01 in Q1 2022[15] - Accounts payable decreased to RMB 2,749,070,254.25 from RMB 2,988,243,259.98, a decrease of 8.01%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,752[10] - The largest shareholder, Liang Yaoming, holds 15.88% of the shares, with a total of 74,191,907 shares[10] - The company reported a total of 71,068,209 shares held by the largest shareholder, Liang Yaoming, representing 7.12% of the total shares[12] Operational Strategy - The company aims to enhance operational efficiency and improve quality and efficiency in 2023, focusing on refined management strategies[5] Research and Development - Research and development expenses for Q1 2023 were ¥131,642,934.47, a slight decrease from ¥142,105,900.23 in Q1 2022[16] - The company has not disclosed any new product or technology developments during the reporting period[12] Mergers and Acquisitions - There are no significant mergers or acquisitions reported in the current quarter[12] Accounting Standards - The company implemented new accounting standards starting January 1, 2023, which may affect the financial statements and reported figures[21]